The association between triglyceride-glucose index and cognitive function in nondiabetic elderly: NHANES 2011-2014.
Cognition
Insulin resistance
NHANES
Nondiabetic elderly
Triglyceride glucose index
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
received:
07
09
2023
accepted:
31
10
2023
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
epublish
Résumé
The relationship between Insulin resistance (IR) evaluated through homeostasis model assessment insulin resistance (HOMA-IR) and cognitive function is controversial among nondiabetic individuals. No study so far has reported the association between the IR evaluated through triglyceride glucose (TyG) index and cognitive function among nondiabetics. This study aims to assess this association among US nondiabetic older elderly. Data were obtained from the 2011-2014 National Health and Nutrition Examination Survey (NHANES). Low cognitive function was evaluated using the Consortium to Establish a Registry for Alzheimer's Disease Battery for immediate word list learning (CERAD-WL) and delayed recall (CERAD-DR) test, the Animal Fluency Test (AFT), and the Digit Symbol Substitution Test (DSST). Logistic regression analyses were conducted to compute the odds ratio (OR) and 95% confidential interval (CI) to examine the association between the TyG index (continuous and quartiles) and low cognitive function. A total of 661 nondiabetic older adults were included with a mean age of 68.62 ± 6.49 years. Compared to the 1st quartile of the TyG index, participants in the TyG index 4th quartile were associated with low cognitive function evaluated through the CERAD test (CERAD-WL and CERAD-DR) [OR: 2.62; 95% CI (1.31, 5.23); P < 0.05]. Subgroup analyses showed that females (OR A high TyG index was strongly correlated with low cognitive function evaluated through the CERAD test (CERAD-WL and CERAD-DR) among US nondiabetic older women. The management of IR in women might be beneficial to primarily prevent low cognitive function among nondiabetic older elderly.
Sections du résumé
BACKGROUND
BACKGROUND
The relationship between Insulin resistance (IR) evaluated through homeostasis model assessment insulin resistance (HOMA-IR) and cognitive function is controversial among nondiabetic individuals. No study so far has reported the association between the IR evaluated through triglyceride glucose (TyG) index and cognitive function among nondiabetics. This study aims to assess this association among US nondiabetic older elderly.
METHODS
METHODS
Data were obtained from the 2011-2014 National Health and Nutrition Examination Survey (NHANES). Low cognitive function was evaluated using the Consortium to Establish a Registry for Alzheimer's Disease Battery for immediate word list learning (CERAD-WL) and delayed recall (CERAD-DR) test, the Animal Fluency Test (AFT), and the Digit Symbol Substitution Test (DSST). Logistic regression analyses were conducted to compute the odds ratio (OR) and 95% confidential interval (CI) to examine the association between the TyG index (continuous and quartiles) and low cognitive function.
RESULTS
RESULTS
A total of 661 nondiabetic older adults were included with a mean age of 68.62 ± 6.49 years. Compared to the 1st quartile of the TyG index, participants in the TyG index 4th quartile were associated with low cognitive function evaluated through the CERAD test (CERAD-WL and CERAD-DR) [OR: 2.62; 95% CI (1.31, 5.23); P < 0.05]. Subgroup analyses showed that females (OR
CONCLUSIONS
CONCLUSIONS
A high TyG index was strongly correlated with low cognitive function evaluated through the CERAD test (CERAD-WL and CERAD-DR) among US nondiabetic older women. The management of IR in women might be beneficial to primarily prevent low cognitive function among nondiabetic older elderly.
Identifiants
pubmed: 37932783
doi: 10.1186/s12944-023-01959-0
pii: 10.1186/s12944-023-01959-0
pmc: PMC10629120
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
188Subventions
Organisme : Research program of Medical and Health Science and Technology Development Plan Project of Shandong Province
ID : 202103070653
Informations de copyright
© 2023. The Author(s).
Références
Medicina (Kaunas). 2022 Jun 30;58(7):
pubmed: 35888595
Alzheimers Res Ther. 2021 Jan 5;13(1):9
pubmed: 33402193
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
JAMA Neurol. 2015 Sep;72(9):1013-20
pubmed: 26214150
Diabetes Care. 2011 Aug;34(8):1766-70
pubmed: 21680719
Diabetes. 2017 Jul;66(7):1957-1963
pubmed: 28389469
Am J Alzheimers Dis Other Demen. 2009 Dec-2010 Jan;24(6):461-8
pubmed: 19759254
Med Clin North Am. 2004 Jul;88(4):787-835, ix
pubmed: 15308380
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
J Alzheimers Dis. 2017;57(2):633-643
pubmed: 28304291
Diabetologia. 2015 Nov;58(11):2545-53
pubmed: 26276262
J Parkinsons Dis. 2018;8(2):259-265
pubmed: 29614702
Neurology. 2022 Aug 9;99(6):e574-e582
pubmed: 35831178
Diabetes Res Clin Pract. 2021 Aug;178:108939
pubmed: 34229005
Front Endocrinol (Lausanne). 2014 Oct 09;5:161
pubmed: 25346723
Acta Diabetol. 2014 Aug;51(4):679-81
pubmed: 24370925
Neurosci Biobehav Rev. 2022 Jun;137:104642
pubmed: 35367221
Endocrinology. 2013 Mar;154(3):1047-54
pubmed: 23337529
Cardiovasc Diabetol. 2022 Jul 1;21(1):123
pubmed: 35778734
Front Cardiovasc Med. 2021 Jan 14;7:628109
pubmed: 33521071
Diabetes Care. 2013 Jun;36(6):1512-21
pubmed: 23275371
J Clin Med. 2021 Jan 18;10(2):
pubmed: 33477579
BMC Psychiatry. 2021 May 25;21(1):267
pubmed: 34030657
PLoS One. 2015 May 12;10(5):e0126804
pubmed: 25965336
Lancet Public Health. 2020 Dec;5(12):e661-e671
pubmed: 33271079
Nat Rev Endocrinol. 2018 Oct;14(10):591-604
pubmed: 30022099
Medicine (Baltimore). 2023 Jun 16;102(24):e34058
pubmed: 37327285
JAMA Ophthalmol. 2017 Sep 1;135(9):963-970
pubmed: 28817745
Drugs. 2023 Mar;83(4):359-365
pubmed: 36856953
Front Aging Neurosci. 2019 Sep 06;11:236
pubmed: 31551756
J Affect Disord. 2022 Nov 1;316:42-49
pubmed: 35952934
Nutr J. 2020 Mar 28;19(1):25
pubmed: 32222145
J Pak Med Assoc. 2022 May;72(5):986-988
pubmed: 35713073
BMJ. 1997 Oct 25;315(7115):1045-9
pubmed: 9366728
BMJ. 2017 Jul 5;358:j2856
pubmed: 28679494
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Diabetes Metab Syndr Obes. 2022 Nov 18;15:3577-3587
pubmed: 36426213
J Gerontol. 1992 May;47(3):P121-8
pubmed: 1573192
Peptides. 1990 May-Jun;11(3):467-72
pubmed: 2199946
Natl Health Stat Report. 2019 Sep;(126):1-23
pubmed: 31751207
Nutr Neurosci. 2023 Mar 28;:1-11
pubmed: 36976719
J Clin Med. 2022 Dec 01;11(23):
pubmed: 36498726
Neurobiol Aging. 2011 Nov;32(11):1942-8
pubmed: 20031276
Drugs. 2021 Aug;81(12):1437-1443
pubmed: 34324167
Front Endocrinol (Lausanne). 2022 Sep 02;13:951689
pubmed: 36120429
Neurotherapeutics. 2019 Jul;16(3):649-665
pubmed: 31364065
Endocr Res. 2022 Feb-May;47(2):89-93
pubmed: 35393913
Diabetes Res Clin Pract. 2011 Sep;93(3):e98-e100
pubmed: 21665314
J Neurol Sci. 2018 May 15;388:97-102
pubmed: 29627040
Diabetol Metab Syndr. 2015 Mar 15;7:20
pubmed: 25798199
Diabetes Care. 2012 Mar;35(3):488-94
pubmed: 22301128
Acta Psychiatr Scand. 2022 Feb;145(2):156-185
pubmed: 34758106
Biol Res Nurs. 2015 Oct;17(5):540-8
pubmed: 25391255
Value Health Reg Issues. 2023 Sep;37:49-52
pubmed: 37315510
Diabetes. 2000 Sep;49(9):1525-33
pubmed: 10969837
Int J Geriatr Psychiatry. 2015 Jun;30(6):551-7
pubmed: 25060738
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6379-6384
pubmed: 30765523
Front Endocrinol (Lausanne). 2022 Aug 05;13:970122
pubmed: 35992100
Eur J Public Health. 2018 Jun 1;28(3):496-503
pubmed: 29140417
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248